1. Drug-related risks

   • Ulrich Klotz

   Editorial Commentary 20 September 2007 Pages: 983 - 984

2. Long-term changes in management following n-of-1 trials of stimulants in attention-deficit/hyperactivity disorder

   • C. Jane Nikles
   • Geoffrey K. Mitchell
   • Alexandra Clavarino

   Clinical Trial 16 August 2007 Pages: 985 - 989

3. Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome

   • Daiji Kato
   • Chiaki Kawanishi
   • Yoshio Hirayasu

   Pharmacogenetics 14 August 2007 Pages: 991 - 996

4. Vitamin D receptor haplotypes protect against development of colorectal cancer

   • Jana Flügge
   • Solveigh Krusekopf
   • Ivar Roots

   Pharmacogenetics 20 September 2007 Pages: 997 - 1005

   

5. Acute myocarditis after massive phenelzine overdose

   • W. Stephen Waring
   • William A. H. Wallace

   Pharmacodynamics 07 September 2007 Pages: 1007 - 1009

   

6. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study

   • Réginald Hulhoven
   • Dominique Rosillon
   • Armel Stockis

   Pharmacodynamics 21 September 2007 Pages: 1011 - 1017

   

7. Population pharmacokinetic analysisof lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART

   • Xavière Panhard
   • Mayeule Legrand
   • the Cophar 1 - ANRS 102 Study Group

   Pharmacokinetics and Disposition 11 August 2007 Pages: 1019 - 1029

   

8. Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration

   • Takenori Niioka
   • Tsukasa Uno
   • Tomonori Tateishi

   Pharmacokinetics and Disposition 16 August 2007 Pages: 1031 - 1038

   

9. Evaluation of limited sampling strategies for tacrolimus

   • Robert A. M. Op den Buijsch
   • Afke van de Plas
   • Otto Bekers

   Pharmacokinetics and Disposition Open access 22 August 2007 Pages: 1039 - 1044

   

10. Pharmacokinetic–pharmacodynamic modeling of the miotic effects of dihydrocodeine in humans

    • Helmut Schmidt
    • Jörn Lötsch

    Pharmacokinetics and Disposition 05 September 2007 Pages: 1045 - 1054

    

11. Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study

    • Joerg Hasford
    • Detlef Schröder-Bernhardi
    • Gerhard Dietlein

    Pharmacoepidemiology and Prescription 14 August 2007 Pages: 1055 - 1061

12. Attitudes toward psychiatric drug treatment: the experience of being treated

    • Carlos De las Cuevas
    • Emilio J. Sanz

    Pharmacoepidemiology and Prescription 16 August 2007 Pages: 1063 - 1067

13. High concordance between self-reported medication and official prescription database information

    • Jari Haukka
    • Jaana Suvisaari
    • Jouko Lönnqvist

    Pharmacoepidemiology and Prescription 22 August 2007 Pages: 1069 - 1074

    

14. Recognition and management of potential drug–drug interactions in patients on internal medicine wards

    • Priska Vonbach
    • André Dubied
    • Stephan Krähenbühl

    Pharmacoepidemiology and Prescription 06 September 2007 Pages: 1075 - 1083

    

15. Why healthy subjects volunteer for phase I studies and how they perceive their participation?

    • Luis Almeida
    • Benedita Azevedo
    • Patrício Soares-da-Silva

    Pharmacoepidemiology and Prescription 20 September 2007 Pages: 1085 - 1094

    

16. Potential drug interactions during a three-decade study period: a cross-sectional study of a prescription register

    • Emelie Åstrand
    • Bengt Åstrand
    • Göran Petersson

    Erratum 25 September 2007 Pages: 1095 - 1095